Epstein David R sold $16K of TEM

Epstein David R sold 250 shares of Tempus AI, Inc. (TEM) at $65.55 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epstein David R
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The sale is modest and unlikely to affect Tempus AI's stock price.

02

Market read

Small insider sale with limited trading relevance.

03

What to watch

Potential future dilution from upcoming equity raises.

Relevance 2/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Director David R. Epstein sold 250 shares of Tempus AI for $16,387.50 via a 10b5‑1 plan.

Expected impact

No material move expected.

Evidence & confidence

The transaction size is small relative to total float and disclosed under a pre‑arranged plan.

Market effects

None

None

None

Counterpoint

Insider sale could signal concerns, but size is too small to infer.

Key entities

  • Tempus AI, Inc.

    AI‑driven healthcare data platform.

  • David R. Epstein

    Director of Tempus AI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.